Abstract
MicroRNAs (miRNAs) are small, non-coding RNAs that can post-transcriptionally regulate gene expression via messenger RNA (mRNA) targeting. During the past few years several miRNA groups emerged as critical components of developmental and pathological processes, among them being cancer. In colorectal cancer (CRC) specifically, numerous miRNA molecules have been identified up- or downregulated functioning as tumor-specific markers with oncogenic and tumor-suppressive properties. Their dysregulation impacts impaired cellular processes such as cell proliferation, apoptosis, angiogenesis, invasion and metastasis. The detection of extracellular miRNAs in plasma and fecal samples of CRC patients tends to provide novel, non-invasive biomarkers in favor of CRC diagnosis and, at the same time, data from in vivo and in vitro CRC models reveal promising therapeutic applications through miRNA inhibition and miRNA delivery.
Keywords: Cancer diagnosis, colorectal cancer, microRNA, oncogene, therapy, tumor suppressor.
Current Pharmaceutical Biotechnology
Title:MicroRNAs in Colorectal Neoplasia: From Pathobiology to Clinical Applications
Volume: 15 Issue: 5
Author(s): Antonios N. Gargalionis, Efthimia K. Basdra and Athanasios G. Papavassiliou
Affiliation:
Keywords: Cancer diagnosis, colorectal cancer, microRNA, oncogene, therapy, tumor suppressor.
Abstract: MicroRNAs (miRNAs) are small, non-coding RNAs that can post-transcriptionally regulate gene expression via messenger RNA (mRNA) targeting. During the past few years several miRNA groups emerged as critical components of developmental and pathological processes, among them being cancer. In colorectal cancer (CRC) specifically, numerous miRNA molecules have been identified up- or downregulated functioning as tumor-specific markers with oncogenic and tumor-suppressive properties. Their dysregulation impacts impaired cellular processes such as cell proliferation, apoptosis, angiogenesis, invasion and metastasis. The detection of extracellular miRNAs in plasma and fecal samples of CRC patients tends to provide novel, non-invasive biomarkers in favor of CRC diagnosis and, at the same time, data from in vivo and in vitro CRC models reveal promising therapeutic applications through miRNA inhibition and miRNA delivery.
Export Options
About this article
Cite this article as:
Gargalionis N. Antonios, Basdra K. Efthimia and Papavassiliou G. Athanasios, MicroRNAs in Colorectal Neoplasia: From Pathobiology to Clinical Applications, Current Pharmaceutical Biotechnology 2014; 15 (5) . https://dx.doi.org/10.2174/1389201015666140519123609
DOI https://dx.doi.org/10.2174/1389201015666140519123609 |
Print ISSN 1389-2010 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4316 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Therapeutic Modulation of Growth Factors and Cytokines in Regenerative Medicine
Current Pharmaceutical Design Genetic and Epigenetic Heterogeneity in Cancer: The Ultimate Challenge for Drug Therapy
Current Drug Targets The Contribution of Nitric Oxide and Carbon Monoxide to Neuronal Function and Development
Central Nervous System Agents in Medicinal Chemistry Prediction and Analysis of Hepatocellular Carcinoma Related Genes Using Gene Ontology and KEGG
Current Bioinformatics Impact of Traditional Therapies and Biologics on Cardiovascular Diseases in Rheumatoid Arthritis
Current Vascular Pharmacology ABC Transporters in Multidrug Resistance and Pharmacokinetics, and Strategies for Drug Development
Current Pharmaceutical Design Membrane Targeted Anticancer Drugs: Potent Inducers of Apoptosis and Putative Radiosensitisers
Current Medicinal Chemistry - Anti-Cancer Agents Poly (ADP-Ribosyl) Polymerase 1 Inhibitors: A Patent Review
Recent Patents on Anti-Cancer Drug Discovery An Update on Clinical Drug Interactions with the Herbal Antidepressant St. Johns wort
Current Drug Metabolism Chemotherapy-Induced Peripheral Neuropathic Pain and Rodent Models
CNS & Neurological Disorders - Drug Targets Non-Genotoxic p53-Activators and their Significance as Antitumor Therapy of Future
Current Medicinal Chemistry Lactate Transporters and pH Regulation: Potential Therapeutic Targets in Glioblastomas
Current Cancer Drug Targets Beyond the "Lock and Key" Paradigm: Targeting Lipid Rafts to Induce the Selective Apoptosis of Cancer Cells
Current Medicinal Chemistry Construction and Analysis of mRNA and lncRNA Regulatory Networks Reveal the Key Genes Associated with Prostate Cancer Related Fatigue During Localized Radiation Therapy
Current Bioinformatics Low Grade Inflammation as a Common Pathogenetic Denominator in Age-Related Diseases: Novel Drug Targets for Anti-Ageing Strategies and Successful Ageing Achievement
Current Pharmaceutical Design Moving Beyond VEGF for Anti-angiogenesis Strategies in Gynecologic Cancer
Current Pharmaceutical Design A Better Platinum-Based Anticancer Drug Yet to Come?
Anti-Cancer Agents in Medicinal Chemistry The Role of Bacterial Lipopolysaccharides as Immune Modulator in Vaccine and Drug Development
Endocrine, Metabolic & Immune Disorders - Drug Targets Tumor Intracellular Redox Status and Drug Resistance-Serendipity or a Causal Relationship?
Current Pharmaceutical Design Silencing GPX3 Expression Promotes Tumor Metastasis in Human Thyroid Cancer
Current Protein & Peptide Science